Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs A Systematic Review and Meta-Analysis

被引:143
|
作者
Kesselheim, Aaron S. [1 ,2 ]
Stedman, Margaret R. [1 ,2 ]
Bubrick, Ellen J. [2 ,3 ]
Gagne, Joshua J. [1 ,2 ]
Misono, Alexander S. [1 ,2 ]
Lee, Joy L. [1 ,2 ]
Brookhart, M. Alan [4 ]
Avorn, Jerry [1 ,2 ]
Shrank, William H. [1 ,2 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Brigham & Womens Hosp, Dept Neurol, Div Epilepsy, Boston, MA 02115 USA
[4] UNC Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA
基金
美国医疗保健研究与质量局;
关键词
SUBSTITUTION; BIOAVAILABILITY; CARBAMAZEPINE; EPILEPSY; DISSOLUTION; IDENTIFICATION; LAMOTRIGINE; MEDICATION; PATIENT; EVENTS;
D O I
10.2165/10898530-000000000-00000
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The automatic substitution of bioequivalent generics for brand-name antiepileptic drugs (AEDs) has been linked by anecdotal reports to loss of seizure control. Objective: To evaluate studies comparing brand-name and generic AEDs, and determine whether evidence exists of superiority of the brand-name version in maintaining seizure control. Data Sources: English-language human studies identified in searches of MEDLINE, EM BASE and International Pharmaceutical Abstracts (1984 to 2009). Study Selection: Randomized controlled trials (RCTs) and observational studies comparing seizure events or seizure-related outcomes between one brand-name AED and at least one alternative version produced by a distinct manufacturer. Data Extraction: We identified 16 articles (9 RCTs, 1 prospective non-randomized trial, 6 observational studies). We assessed characteristics of the studies and, for RCTs, extracted counts for patients whose seizures were characterized as 'controlled' and 'uncontrolled'. Data Synthesis: Seven RCTs were included in the meta-analysis. The aggregate odds ratio (n = 204) was 1.1(95% CI 0.9, 1.2), indicating no difference in the odds of uncontrolled seizure for patients on generic medications compared with patients on brand-name medications. In contrast, the observational studies identified trends in drug or health services utilization that the authors attributed to changes in seizure control. Conclusions: Although most RCTs were short-term evaluations, the available evidence does not suggest an association between loss of seizure control and generic substitution of at least three types of AEDs. The observational study data may be explained by factors such as undue concern from patients or physicians about the effectiveness of generic AEDs after a recent switch. In the absence of better data, physicians may want to consider more intensive monitoring of high-risk patients taking AEDs when any switch occurs.
引用
收藏
页码:605 / 621
页数:17
相关论文
共 50 条
  • [21] Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use
    Juan P. Brito
    Joseph S. Ross
    Yihong Deng
    Lindsey Sangaralingham
    David J. Graham
    Yandong Qiang
    Zhong Wang
    Xiaoxi Yao
    Liang Zhao
    Robert C. Smallridge
    Victor Bernet
    Nilay D. Shah
    Kasia J. Lipska
    Endocrine, 2021, 74 : 592 - 602
  • [22] Association between use of antiepileptic drugs and fracture risk: A systematic review and meta-analysis
    Shen, Chunhong
    Chen, Feng
    Zhang, Yinxi
    Guo, Yi
    Ding, Meiping
    BONE, 2014, 64 : 246 - 253
  • [23] Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use
    Brito, Juan P.
    Ross, Joseph S.
    Deng, Yihong
    Sangaralingham, Lindsey
    Graham, David J.
    Qiang, Yandong
    Wang, Zhong
    Yao, Xiaoxi
    Zhao, Liang
    Smallridge, Robert C.
    Bernet, Victor
    Shah, Nilay D.
    Lipska, Kasia J.
    ENDOCRINE, 2021, 74 (03) : 592 - 602
  • [24] BRAND-NAME TO GENERIC SUBSTITUTION OF ANTIEPILEPTIC DRUGS (AED) DOES NOT LEAD TO SEIZURE-RELATED HOSPITALIZATION: A POPULATION-BASED CASE-CROSSOVER STUDY
    Polard, E.
    Nowak, E.
    Happe, A.
    Birabee, A.
    Oger, E.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E114 - E114
  • [25] DOUBLE-BLIND CROSSOVER BIOEQUIVALENCY STUDY OF BRAND-NAME VERSUS GENERIC CARBAMAZEPINE IN PARTIAL SEIZURE PATIENTS
    OLES, KS
    PENRY, JK
    SMITH, LD
    DEAN, JC
    RIELA, TR
    ANNALS OF NEUROLOGY, 1990, 28 (02) : 263 - 263
  • [26] IMPACT OF EDUCATION BY CLINICAL PHARMACISTS ON PHYSICIAN AMBULATORY CARE PRESCRIBING OF GENERIC VERSUS BRAND-NAME DRUGS
    ERRAMOUSPE, J
    DICP-THE ANNALS OF PHARMACOTHERAPY, 1989, 23 (10): : 770 - 773
  • [28] Competition and price among brand-name drugs in the same class: A systematic review of the evidence
    Sarpatwari, Ameet
    DiBello, Jonathan
    Zakarian, Marie
    Najafzadeh, Mehdi
    Kesselheim, Aaron S.
    PLOS MEDICINE, 2019, 16 (07)
  • [29] A Meta-Analysis and Systematic Review of Antiepileptic Drugs for Seizure Prophylaxis on Long-Term Functional Outcomes in Patients With Acute Intracerebral Hemorrhage
    Spoelhof, Brian
    Sanchez-Bautista, Julian
    Zorrilla-Vaca, Andres
    Kaplan, Peter W.
    Farrokh, Salia
    Mirski, Marek
    Freund, Brin
    Rivera-Lara, Lucia
    STROKE, 2018, 49
  • [30] Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D
    Dusetzina, Stacie B.
    Sarpatwari, Ameet
    Carrier, Michael A.
    Hansen, Richard A.
    Keating, Nancy L.
    Huskamp, Haiden A.
    JAMA INTERNAL MEDICINE, 2021, 181 (12) : 1605 - 1611